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Abstract
Herpes simplex type 1 (HSV1) replicates in epithelial cells and secondarily enters local sensory neuronal processes, traveling
retrograde to the neuronal nucleus to enter latency. Upon reawakening newly synthesized viral particles travel anterograde
back to the epithelial cells of the lip, causing the recurrent cold sore. HSV1 co-purifies with amyloid precursor protein (APP),
a cellular transmembrane glycoprotein and receptor for anterograde transport machinery that when proteolyzed produces
A-beta, the major component of senile plaques. Here we focus on transport inside epithelial cells of newly synthesized virus
during its transit to the cell surface. We hypothesize that HSV1 recruits cellular APP during transport. We explore this with
quantitative immuno-fluorescence, immuno-gold electron-microscopy and live cell confocal imaging. After synchronous
infection most nascent VP26-GFP-labeled viral particles in the cytoplasm co-localize with APP (72.8+/26.7%) and travel
together with APP inside living cells (81.1+/228.9%). This interaction has functional consequences: HSV1 infection decreases
the average velocity of APP particles (from 1.1+/20.2 to 0.3+/20.1 mm/s) and results in APP mal-distribution in infected
cells, while interplay with APP-particles increases the frequency (from 10% to 81% motile) and velocity (from 0.3+/20.1 to
0.4+/20.1 mm/s) of VP26-GFP transport. In cells infected with HSV1 lacking the viral Fc receptor, gE, an envelope
glycoprotein also involved in viral axonal transport, APP-capsid interactions are preserved while the distribution and
dynamics of dual-label particles differ from wild-type by both immuno-fluorescence and live imaging. Knock-down of APP
with siRNA eliminates APP staining, confirming specificity. Our results indicate that most intracellular HSV1 particles
undergo frequent dynamic interplay with APP in a manner that facilitates viral transport and interferes with normal APP
transport and distribution. Such dynamic interactions between APP and HSV1 suggest a mechanistic basis for the observed
clinical relationship between HSV1 seropositivity and risk of Alzheimer’s disease.
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Introduction
Herpes simplex virus type I (HSV1), an alpha herpesvirus, is
endemic in the general population, causing life-long latent
infections in neurons. Like many other viruses, after assembly in
the nucleus HSV1 nucleocapsids transport outwards through the
cytoplasm towards the cell surface both in epithelial cells and in
neurons [1,2,3,4,5,6,7]. While anterograde transport of newly
synthesized virus to the epithelial cell surface and from neuronal
cell bodies to the mucosal membrane is crucial for viral
propagation to a new host, neither the cellular nor viral molecular
mediators are known.
How HSV1 coordinates assembly with transport remains an
important unresolved question. Such coordinated assembly may
differ between epithelial cells and neurons, and between different
types of alpha herpesviruses, which has led to some controversy.
Recent evidence suggests that the swine alpha herpesvirus,
pseudorabies virus (PRV), travels inside membranated vesicles
within neurons [8], a mechanism of anterograde transport also
believed to be invoked in epithelial cells by HSV1 (reviewed in
[9]). Newly synthesized HSV1 capsids travel outward from the
nucleus either independently to be assembled with other
components at the cell periphery [3,6,10,11], together as
enveloped particles inside a second, Golgi-derived, cellular
membrane [12,13,14,15,16,17], or both [1,18,19,20]. Electron-
microscopy of infected cells demonstrates capsids both free in the
cytoplasm as well as inside intracellular membrane systems
[9,15,16,19].
To coordinate envelopment with transport, the virus must take
advantage of cellular synthetic and transport machinery. Such co-
option of transport machinery may underlie HSV1 cellular
pathology, injuring cells by interfering with this normal important
cellular process. Exploiting green-fluorescent-protein (GFP)-la-
beled HSV1 as a tool to uncover cargo motor receptors led us to
discover that the cellular transmembrane glycoprotein, amyloid
precursor protein (APP), is a component of isolated HSV1
intracellular viral particles, with ,1,000 or more copies on
average per particle [17]. Since altered APP is a known risk factor
for Alzheimer’s disease [21,22], which has been linked to transport
defects [23,24,25,26], interactions of APP with HSV1 are
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viral particles physically associated with APP are transported in the
anterograde direction when injected into the giant axon of the
squid [17]. Furthermore, a 15-amino acid ‘‘zipcode’’ from the
cytoplasmic C-terminus of APP mediates anterograde transport of
fluorescent beads in the axon [27]. Thus APP hitches exogenous
cargo to cellular anterograde motor machinery for transport,
which suggests one mechanism the virus may exploit to travel to
the cell surface.
While APP is physically associated with viral particles isolated
from infected cell cytoplasm, it was not among the proteins
identified by mass spectroscopy of extracellular infectious particles
[23]. Thus it is unknown whether APP joins viral particles during
packaging inside the cell, or during the procedure to isolate viral
particles, which includes disruption of infected cells, centrifuga-
tions and sucrose density fractionation, which could redistribute
molecules not normally together.
We therefore set out to determine whether APP co-localizess
with virus inside cells, and whether interplay between virus and
APP-containing cellular membranes enhances transport of nascent
virus from peri-nuclear region to the cell surface and/or affects
APP transport dynamics. Two approaches were developed to
assign viral particles as either out-going or in-coming: Synchro-
nizing infection to a narrow time window and thus limiting in-
coming viral particles during viral production; and live imaging.
We used a GFP-tagged virus, VP26-GFP HSV1, to visualize viral
particles as they form and travel. VP26-GFP labeling has proven
to be a spectacular tool to image viral capsid movements [28].
VP26 is a small protein that attaches to the major capsid protein,
VP5, by binding to the outer surface of hexons [29,30]. VP26-
GFP labels viral capsids without disturbing viral function
[28,31,32]. Here we explored dynamic interactions between viral
capsids and cellular APP inside epithelial cells during viral egress
in synchronously infected cells. While epithelial cells and neurons
may differ in details of transport mechanisms, the major
mechanisms are likely to be the same: microtubule-based transport
by kinesin and dynein families of molecular motors. For these
studies we developed a method to limit infection to a short time
window such that .90% of cytoplasmic capsids in productively
infected cells represent newly synthesized virus. We then probed
VP26-GFP-HSV1-infected cells for APP by quantitative immu-
nohistochemistry and immunogold electron-microscopy, and also
performed dual-color confocal time-lapse imaging of fluorescent-
protein labeled capsids (VP26-GFP) interacting with labeled APP
(APP-mRFP) inside living cells. We observed frequent dynamic
interactions between cellular APP and out-going newly synthesized
viral particles. APP interplay greatly increased the propensity of
VP26-GFP capsids to move. These studies also reveal that HSV1
infection and subsequent capsid-APP interactions decrease the
transport dynamics and provoke an abnormal subcellular
distribution of cellular APP.
Results
Synchronizing infection to distinguish in-coming from
out-going particles in the cytoplasm
We found that when confluent cell cultures are continuously
exposed to virus, individual cells may acquire cytoplasmic viral
particles from the media or through junctional contacts with other
cells at any time during incubation. In such cultures individual
viral particles in the cytoplasm of fixed cells cannot readily be
identified as either incoming or outgoing. Since molecular motors
mediating inward versus outward transport are different, the
composition of incoming and outgoing viral particles must also
differ. Without a reliable method to distinguish incoming from
outgoing viral particles conclusions about the molecular compo-
sition of out-going particles is difficult. What is needed is a method
to limit incoming particles. To do this we developed a natural yet
rigorous infection protocol of sub-confluent cultures to limit in-
coming virus within a short time period such that all infected cells
were at a similar stage of infection. Since our goal was to image
exiting viral particles, we did not aim for a uniform infection of all
cells. We validated the protocol by counting VP26-GFP-labeled
particles in the cytoplasm of infected cells at successive time points
after various infection protocols (Figure 1 and Figure S1). Infected
cells were identified by the presence of VP26-GFP in the nucleus,
the source for out-going cytoplasmic viral particles. In productive
infections, new capsids assemble first in the nucleus and then move
outwards through the cytoplasm. Thus only cytoplasmic VP26-
GFP particles in cells with nuclear VP26-GFP were considered
potentially outgoing capsids. Cytoplasmic VP26-GFP particles in
cells without nuclear GFP were considered incoming. The vast
majority of cytoplasmic GFP-particles also stained for VP5
(92.862.9%, n=2927), the major capsid protein, confirming
that GFP-labeled particles primarily represent viral capsids (Figure
S2).
While Campodelli-Fiume et al. reported that gD over-
expression inhibits infection by measuring viral protein synthesis
in cells expressing gD [33], both they and we observe viral
particles in the cytoplasm of gD expressing cells [34]. Another
group counted the number of viral particles stalled in the
cytoplasm and correlated this with the genome/pfu ratios as an
indirect measure of the number of defective particles in viral
preparation that may enter a cell but not travel to the nucleus [31].
In a careful, quantitative study of various protocols previously
used to block continuous viral entry, we found that none
eliminated incoming viral particles in infected cell cytoplasm,
including viral expression of gD or the presence of inhibitory
human serum in the media. Since our focus was to witness HSV1-
APP interactions in out-going cytoplasmic particles through
immuno-staining and dynamic imaging, we concluded that
reliance on gD expression or human serum to block re-infection
was inadequate. We used a combination approach to limit
infection to a narrow time frame (1 hr) as detailed in Materials and
Methods. Quantitative analysis of cytoplasmic VP26-GFP-parti-
cles 4–5 hr after infection of sub-confluent cells with our
synchronization protocol, a time point before emergence of newly
synthesized capsids from the nucleus, revealed that in our
synchronized infections only 3.3+/22.3 VP26-GFP particles were
present in the cytoplasm, indicating that on average 3 viral
particles entered the cell or had been retained in the cytoplasm
during 4–6 hr after the synchronized infection window (see Figure
S1). This is equivalent to the best viral preparations previously
reported [31]. We reasoned therefore that any particular
cytoplasmic particle, even at later time points, in a cell with
.30 particles in the cytoplasm has .90% chance of being out-
going when cells are infected during a one-hour time window
according to this synchronous infection protocol.
HSV1 infection dramatically alters the distribution of
cellular APP
APP was visualized in mock-infected cells and in cells
synchronously infected with VP26-GFP HSV1 by immuno-
fluorescence (Figure 2). In uninfected cells, a tuft of APP staining
to one side of the nucleus overlapped with TGN46, and thus likely
represents the trans-Golgi network (Figure 2A) [35,36]. In
contrast, infected cells displayed APP staining throughout the
cytoplasm by 7 hr p.i. (Figure 2B). Similar changes in staining
Interplay between HSV1 and Cellular APP
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17966patterns were seen in HSV1 infected human retinal epithelial cells
(ARPE-19), Hela cells, and neuronal cell lines (PC12 and SHSY
5Y), although some cells retain the peri-nuclear position of the
Golgi longer after infection than others. Redistribution of APP
staining pattern was observed with three different anti-peptide C-
APP
695 antibodies from three different vendors (Sigma, against aa
676-695, Zymed against aa 673–695 and Chemicon against aa
686–695). The increased brightness of APP staining was confirmed
by Western blot (Figure 2C) and is consistent with reports showing
increased production of amyloid beta (A-beta), a product of APP,
in HSV1 infected neurons [37,38]. Since epithelial cells lack the
enzymes to produce A-beta, excess APP expression that might be
converted to A-beta in neurons would remain detectible as the full-
length protein in epithelial cells. Notably, no additional bands are
detected in Western blots of virally infected versus uninfected cells,
demonstrating that the increase in APP antibody staining is not
due to any anti-herpesvirus activity among the anti-APP
antibodies. Finally we compared the ,90–110 kD bands recog-
nized by anti-APP with the protein banding pattern of isolated
virus detected in a parallel lane of the same blot stained with
amido black (Figure 2D). The bands migrating at ,90–110 kD
detected by anti-APP were similar to those in uninfected cells, and
appear to correspond to the viral proteins, VP8–10, identified in
metabolically labeled virions by Honess and Roizman [39].
HSV1 encodes an immunoglobulin Fc receptor, gE/gI, an
envelope glycoprotein complex which binds the non-antigen-
binding domain of immunoglobulin [40,41,42]. Like many viral
proteins, gE may play more than one role– in addition to Fc
binding, it appears to be required for anterograde transport of
virus in neurons [43,44,45]. Although gE is classified as non-
essential for growth in epithelial cells, deletions of gE do affect viral
behavior in these cells: for example gE deletions result in smaller
than normal plaques in epithelial monolayers [46], and display
defects in transmission from infected epithelial cells to sensory
neurons [44]. Since neurons and epithelial cells use similar
machinery for transport, gE is also likely to be involved in
intracellular transport in epithelial cells, although this process
would not be essential to viral propagation in these cells, it may be
responsible for smaller plaque size due to fewer virions reaching
the cell surface for release.
To test whether the APP staining we observed was a result of
specific antigen binding or an artifact of antibodies binding to the
viral Fc receptor, gE/gI, we performed several control experi-
ments: a) staining infected cells in parallel for APP and for a
nuclear antigen, histone 3, using anti-histone rabbit antibodies of
the same purity and at the same concentration as the anti-APP
rabbit antibodies; b) staining cells infected with a virus deleted in
gE; and, as shown later in this paper, c) knocking down APP with
siRNA.
First, cells were stained in parallel for APP and for histones with
rabbit primary antibodies and the same secondary antibody, all
with similar purity and concentration, and imaged with the same
camera settings. Viral particles were stained with anti-APP but not
with anti-histone antibodies, which appropriately stained the
nucleus predominantly (Figure S4).
Figure 1. Synchronization of viral infection. (A) Diagram of the
"in-coming/out-going" problem. Constitutive infections (left column), in
which virus is added to the culture and allowed to remain throughout
incubation, results in continuous entry of virus and mixing of in-coming
and out-going viral particles in the cytoplasm. In synchronized infection
(right column) viral exposure is limited by removal of the media, release
of adherent virus from cell surface with acid-glycine and inactivation
with human serum, resulting in few in-coming virus in the cytoplasm at
later stages. Sub-confluent cultures are required to reduce viral
transmission through cell-cell junctions. (B) An example of digital
images used to quantify cellular locations of VP26-GFP particles. In this
example, cells synchronously infected with VP26-GFP HSV1 (green)
were fixed at 7 hr p.i., and counterstained with DAPI (blue). Images
were collected by widefield fluorescence to detect VP26-GFP particles
throughout the full thickness of the cells. Infected cell nuclei containing
VP26-GFP appear turquoise at this exposure. Most of these infected
cells display multiple viral particles in the cytoplasm. One cell (arrow)
with no nuclear GFP fluorescence has three cytoplasmic GFP-particles
(arrowheads) that therefore are in-coming virus. (C) Higher magnifica-
tion of the boxed region in B in the GFP channel to show absence of
diffuse nuclear fluorescence. Red arrows indicate two of the three GFP
particles in this cell. See Figure S1 for quantification.
doi:10.1371/journal.pone.0017966.g001
Interplay between HSV1 and Cellular APP
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17966Next, we infected cells with HSV1 deleted in the gE gene,
gEnull. Parallel cultures were infected with the parental strain, and
the gE deletion virus with the gE gene re-inserted (gE rescue) [45].
The increased staining for APP and its redistribution after
infection was still apparent in cells infected with gEnull virus.
APP distribution in cells infected with either the parental strain or
gE rescue infected cells was indistinguishable from that of cells
infected with VP26-GFP virus (Figure 3A). In 3D images at higher
magnifcation obtained by deconvolution of z-stacks, APP staining
of gEnull viral particles was common among viral particles near
the nucleus and less frequent in the peripheral cytoplasm
(Figure 3B and Movie S1), an observation we will explore in
more depth below.
Cytoplasmic HSV1 particles co-localize preferentially with
APP and with viral envelope glycoproteins and not with
LAMP2, another cellular membrane glycoprotein, by
immunofluorescence
To characterize APP-capsid assemblies in more detail, we
double-stained cells synchronously infected with VP26-GFP-
HSV1 for APP and a viral envelope protein (either gE or gD) in
cultures fixed at 7–9.5 hr p.i. (Figure 4 and Figure S5). The
presence of a viral envelope protein together with the VP26-GFP-
labeled capsid would support the notion that particles co-localizing
with cellular APP were maturing viral particles undergoing
secondary envelopment.
A high proportion of VP26-GFP particles throughout the
cytplasm co-localized with both APP and gE: 72.866.7%
(Figure 4A–D). VP26-GFP particles were rarely found without
APP (3.061.7%). Thus co-localization with APP was statistically
significant. Most importantly, one fifth of the VP26-GFP particles
stained for gE but not for APP (21.865.5%), evidence that APP
staining is not due to non-specific binding of the anti-APP
antibody to gE via its Fc receptor function. Bleed-through between
channels was undetectable (Figure 4B). Intensity profiles on a
pixel-wise basis showed precise coincidence of intensity peaks for
VP26-GFP with both APP and gE staining (Figure 4C). Viral gD
displayed similar co-localization with GFP-particles and APP
(Figure S5A–D). These results support other reports that viral
capsids meet envelope in the cytoplasm during secondary
envelopment when the envelope, with its glycoproteins, engulfs
the particle [47], and extends these findings to identify a cellular
membrane protein involved in this event.
At higher magnification with split channels VP26-GFP particles
were uniform in size and shape, whereas particles stained for APP
or either of the viral glycoproteins, gD or gE, varied in shape and
size (Figure 4B). In some cases the APP stain surrounded the GFP-
particle and in others the overlap with GFP-particle was partial, as
if the capsid were attached to the surface of the vesicle or budding
into it, likely reflecting the different capsid-membrane interactions
seen by electron-microscopy [16,19,48].
Co-localization of viral particles with APP beyond the Golgi
region was also biologically specific, since another organelle
membrane protein, LAMP2, did not co-localize, except within the
Golgi complex where membrane proteins are glycosylated
(Figure 4E–H). LAMP2, a lysosome-associated membrane glyco-
protein [49], co-localized with only a few GFP-particles in the
cytoplasm beyond the peri-nuclear area (7.669.4%) (Figure 4E–
H). GFP-particles stained for both APP and LAMP2 were only
slightly more frequent (22.365.9%) (Figure 3H). This finding is
similar to the sparse co-localization of HSV1 glycoproteins with
LAMP1 previously reported [50], and demonstrates that co-
localization of viral particles with APP is specific–i.e. antibodies
Figure 2. APP relocalizes in infected cells. (A) APP (red) co-
localizes with TGN46 (green) in a compact tuft to one side of the
nucleus (DAPI, blue) representing the trans-Golgi network in mock
infected cells. (B) In cells infected with VP26-GFP HSV1 (green), APP
(red) is distributed in particles throughout the cytoplasm at 7 hr p.i.
Nuclei are stained with DAPI (blue). (C) Western blotting of uninfected
(u) and infected (i) cells with anti-APP, anti-actin (loading control) and
anti-VP5 (viral capsid) demonstrates significant increased amound of
APP in infected cells. Actin bands remain similar, and VP5, as expected,
is only detected in lanes loaded with infected cell lysate. Note no new
APP bands are detected in the infected versus uninfected cell lysates.
(D) Isolated virus separated on 7.5% SDS-PAGE and stained with amido
black for protein and probed for APP by Western blotting with the same
antibodies used for immuno-fluorescence. Note that only the 90–
110 kD doublet representing APP is detected by anti-APP, with no
additional viral protein bands detected. See also Figure S2 for split
channels and Figure S3 for histone staining.
doi:10.1371/journal.pone.0017966.g002
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particles.
APP surrounds membranated viral particles by confocal
and immuno-gold electron microscopy
First, to ensure that co-localization was not due to superimpo-
sition of separate particles from the full-thickness wide-field image,
we captured images by confocal microscopy with 0.8 mm-thick
optical sections (Figure 5). A gallery of images of individual
particles shows GFP-particles singly or in clusters encircled by
both viral envelope glycoproteins and APP (Figure 5B). Most
VP26-GFP-particles are surrounded by membrane proteins as if
inside a membrane compartment. Again, single-labeled VP26-
GFP-labeled particles were rare (3.262.0%), while a high
percentage of GFP-particles stained for both envelope glycopro-
teins and APP (78.465.7%) (Figure 5C). This confirms the co-
localization seen in wide-field images, and provides additional
detail of the APP-capsid interaction.
Co-localization of APP with viral particles was also detected
at the ultrastructural level by immuno-gold thin section electron-
microscopy (Figure 5D–E and Figure S6). Anti-APP antibodies
were visualized by 10 nm protein A-gold particles in thin
sections of infected cells where viral particles at various stages of
maturation were clearly identifiable. Gold particles decorated
membranated viral particles in the cytoplasm of infected cells, as
well as membrane systems closely adjacent to viral particles, and
both the clusters of viral particles inside larger membrane-bound
organelles and the surrounding organelle membrane (Figure S6).
Non-relevant polyclonal rabbit antibodies used in parallel on
the same sections do not label intracellular HSV1 particles
(Figure 5E), membranes in close proximity to viral particles,
or clusters of viral particles within a larger membrane com-
partment (Figure S6). Immunogold labeling of uninfected cells
was sparse, with only a few gold particles found within Golgi
regions.
Thus, membranes containing cellular APP are physically
associated with membranated cytoplasmic HSV1 at the ultra-
structural level.
siRNA knock-down of APP demonstrates specificity of
APP-staining of peripheral viral particles
Anti-APP stained centrally located viral particles in both
wildtype and gEnull HSV1-infected cells which demonstrated
that this staining pattern was not a consequence of antibodies
binding non-specifically to the viral Fc receptor, gE (Figures 2, 3,
4, 5). However, there was less APP staining of peripheral particles
in gEnull-infected cells than in wildtype. This result could either be
because there is some low level of antibody binding to the viral Fc
receptor or because gE is required to retain APP-containing
membranes during viral particle transit to the surface.
To distinguish between these possibilities we knocked down
APP expression using siRNA. If viral particles expressing gE do
not stain for anti-APP after APP knock-down, this would
demonstrate that anti-APP label is not due to the viral Fc
receptor, and suggest that gE may mediate retention of APP-
containing membranes to emerging viral particles during their
maturation and transit to the cell periphery.
First, we confirmed knock-down by Western blotting in mock-
and HSV1-infected cells, comparing no siRNA, non-silencing
siRNA [51] or specific siRNA for human APP (Figure 6). In cells
Figure 3. APP co-localizes with gEnull virus. A representative example of a cell infected with gE null virus stained for APP (red), gE (far red), and
VP5 (green), the major capsid protein. (A) Low magnification wide-field image of the three channels, APP, VP5, and gE shown in color with merged
channels (left), and then each individual channel, as labeled, of the same image. (B) Higher magnification of the boxed region shown in (A) and
rendered in 3D. A Z-stack of 45 focal planes captured at 0.35 mm intervals was deconvolved using iterative processing and rendered in 3D. In four
angles of rotation, co-localization of green VP5 capsids and red APP membranes throughout the cytoplasm of a cell infected with gEnull virus is
shown. See Movie S1 for a full rotation of the 3D stack shown in (B).
doi:10.1371/journal.pone.0017966.g003
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,90–110 kDa APP bands by Western blotting, while mock-
infected and non-silencing siRNA retained similar band intensity
for APP. Actin, a loading control, remains consistent across all 6
treatments.
The immunofluorescence pattern of APP staining of VP26-GFP
HSV1 infected cells after transfection with non-silencing siRNA
was similar to untreated cells (Figure 7A). In contrast, cells
transfected with APP-specific siRNA displayed no detectable
staining of cytoplasmic viral particles despite an abundance of gE,
which often co-localizedd with VP26-GFP particles (Figure 7B).
Faint nuclear fluorescence of anti-APP staining in APP knocked-
down cells most likely represents residual APP.
Live imaging of capsid-APP dynamics
The results described above demonstrate a high frequency of
interactions between intracellular APP and outgoing VP26-GFP-
labeled viral particles. To discover whether interplay with APP
makes a functional contribution to viral transport, we performed
live confocal imaging of cells expressing mono-red-fluorescent-
protein-labeled APP (APP-mRFP) infected with VP26-GFP-
HSV1. Direct visualization of dynamic interactions does not
require fixation and antibody staining, and also provides dynamic
imaging of double-label viral particles. First, as a control, we
confirmed that the mRFP signal represented APP by counter-
staining fixed transfected/HSV1-infected cells with anti-APP
antibodies. The majority (.95%) of mRFP particles also stained
for APP by immunofluorescence (not shown), demonstrating that
mRFP signal represents the APP-mRFP fusion protein.
VP26-GFP particles were co-localized with APP-mRFP and the
two labels moved together through the cytoplasm (Figure 8A–B
and Movie S2). When VP26-GFP-labeled particles left the nucleus
they were quickly met by APP-mRFP vesicles. In these flat
cells (,20 mm thick in our thin section electron-microscopy of
scraped Vero cells), most particles moved in the x-y plane and
could be followed until reaching the lateral borders [52]. On
average, more than two-thirds of all VP26-GFP particles
co-localized with mRFP during any 300-frame 10 min video
sequence (70621%).
The tracks followed by APP-VP26-GFP assemblies varied
(Figure 8B). While some double-labeled particles moved smoothly
in one direction, making steady progress towards the cell surface,
others followed a zigzag pattern. This zigzagging contrasts with
the linear movements of APP-YFP in neuronal processes [53].
Since active transport depends on microtubules, irregular tracks
could be produced by viral-induced pathologic alterations in the
underlying microtubule network [54]. Indeed, the microtubule
network was altered after infection even at early time points (7 hr
Figure 5. Confocal and immuno-gold electron microscopy demonstrate co-localization of both viral (gE) and cellular (APP)
membrane proteins with VP26-GFP particles. (A) Example of a 0.8 mm optical section by confocal imaging of a cell infected with VP26-GFP
HSV1 (green), fixed at 8.5 hr p.i., and stained for cellular APP (red) and viral glycoprotein, gE (blue). (B) Galleries of particles showing the co-
localization of VP26-GFP with gE and APP. (C) Histogram showing the percentage of VP26-GFP particles in each category. VP26-GFP alone (3.262.0%),
with APP (5.962.4%), with gE (12.465.6%) and with both APP and gE (78.465.7%). 569 particles in 5 cells were counted. (D) Thin section immunogold
electron microscopy of HSV1 infected cells probed with anti-C-APP with protein-A linked 10 nm gold particles. Note single and multiple gold particles
decorating membranes surrounding viral capsids in the cytoplasm. Bar=100 nm. (E) Parallel sections from the same EM block treated with
an irrelevant rabbit antibody of similar purity and dilution and probed with protein-A gold. Note the absence of gold labeling of viral particles. Also
see Figure S5 for co-localization of VP26-GFP particles with APP and viral protein gD, and Figure S6 for additional immunogold electron
micrographs.
doi:10.1371/journal.pone.0017966.g005
Figure 4. Out-going cytoplasmic VP26-GFP particles co-localize with APP and not with LAMP2. Cells were synchronously infected with
VP26-GFP HSV1 (green) and fixed at 7 hr p.i.. (A–D) Examples of infected cells stained for gE (blue) and APP (red). In (B) a high magnification of boxed
region in (A) is shown. A white arrow indicates one of the particles displaying all three labels (gE, APP and VP26). Particles with APP only (white
arrowhead) or gE and VP26 (pink arrowhead) are indicated. (F–H) Examples of infected cells stained for LAMP2 (blue) and APP (red). In (F) a high
magnification of the boxed regions in (E) is shown. White arrows indicate APP and gE, pink arrowheads indicate LAMP2, and yellow arrowheads
indicate APP alone. (C and G) Intensity profiles along a line (white) drawn across the merged image in (A) and (E). Arrows indicate the superposition of
peaks for each channel. (D and H) Histograms showing the percentage of VP26-GFP particles in each category. VP26-GFP alone (D: 3.061.7% and H:
11.863.9%) or with APP (D: 2.061.5% and H: 61.3614.7%); VP26-GFP with gE (D: 21.865.5%) or with LAMP2 (H: 4.661.6%); and VP26-GFP with both
APP and gE (D: 72.866.7%), or both APP and LAMP2 (H: 22.368.7%). Experiments were performed in triplicate, and 2085 particles in 11 cells were
counted in D and 1592 particles in 9 cells in H. See Figure S5 for triple label of gD instead of gE, with APP and VP26-GFP.
doi:10.1371/journal.pone.0017966.g004
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Figure S7). Mock-infected cells demonstrated the usual microtu-
bule-organizing center (MTOC) located at one side of the nucleus
with the typical spray of microtubules emanating from it towards
the cortex (Figure 8C). In contrast, in HSV1-infected cells the
MTOC was not identifiable, and the microtubule spray was
disorganized with microtubules appearing curled, bundled, and
lying both perpendicular and parallel to the cellular cortex
(Figure 8D and Figure S7B and C). While the Lippe lab has
reported that Golgi and microtubule stability in viral infection is
variable [32], in these Vero cells this was not the case–all infected
cells across the culture displayed microtubule disarray. By
quantitative analysis of confocal imaging, many GFP-labeled
particles (87% +/2 0.1%) were found adjacent to or touching
microtubules (Figure S7C).
A functional link between APP-compartments and HSV1
became obvious when comparing the dynamics of VP26-GFP-
particles with and without APP in cells expressing low levels of
APP-mRFP. While velocities of VP26-GFP particles that moved
were similar (Figure 8E), the propensity for a particle to move was
much lower for VP26-GFP alone compared to VP26-GFP/APP-
mRFP particles (Figure 8F). The majority of double-label particles
(81628%) traveled together through the cytoplasm for long
distances (up to 60 mm, three times the diameter of the nucleus)
(Figure 8F and Table S1). Some GFP-particles appeared to ride
inside and some on the outside of motile APP-labeled membrane
compartments. Some GFP particles joined, left, and re-joined
these mRFP-labeled structures. In contrast to frequent movements
of APP-VP26-particles, movements of VP26-GFP particles not
associated with APP-mRFP were rare (10.161.1% motile,
88.961.1% immotile). Velocity of all particles that did move
was similar, suggesting that similar transport machinery was in
play.
While VP26-GFP particles traveled more frequently when
associated with APP-mRFP, the opposite was the case for APP-
mRFP particles, for which virus association decreased both
velocity and propensity to move. Small APP-mRFP particles in
uninfected cells moved at 1.1+/20.2 mm/sec instantaneous
velocity, while APP-mRFP particles in infected cells with or
without viral particles moved more slowly (0.3+/20.1 mm/sec)
(see Figure 8E and F, Table S1). Hence infection with HSV1 and
association of APP with viral particles affects the dynamic
movements of emerging viral particles as well as of cellular APP-
vesicles.
Figure 7. Knockdown of APP expression eliminates immuno-fluorescent staining of VP26-GFP particles by anti-APP antibodies. (A)
Representative example of a cell treated with non-silencing control siRNA, infected with VP26-GFP HSV1 (green), fixed at 7 hr p.i. and stained for APP
(red), gE (blue). APP staining is bright and diffuse, and co-localizes with VP26-GFP viral particles (arrows). (B) Representative example of a cell treated
in parallel to the cell shown in (A) but with siRNA for APP. Note the absence of most APP staining, while gE staining of viral particles remains strong.
doi:10.1371/journal.pone.0017966.g007
Figure 6. APP knock-down by siRNA decreases APP protein
.90% by Western blotting. HSV1 infected cells were transfected in
parallel with either vehicle alone (None), non-silencing RNA (Ctrl) or
siRNA against APP (APP). After 48 hr cells were scraped into lysis buffer,
and loaded in parallel on a 10% gel for electrophoresis followed by
transfer to nitrocellulose. The blot was divided in two horizontally, the
top half probed for APP and the lower half for actin, a loading control.
Non-silencing siRNA has little effect, while siRNA for APP decreases APP
band intensity almost entirely, with no significant effect on actin.
doi:10.1371/journal.pone.0017966.g006
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kinesin-driven transport, with the observed maximum velocity of
2.0 mm/s and average instantaneous velocity of 0.460.1 mm/s
(n=118 particles, from 20 cells in independent movies) (Figure 8E
and Table S1).
When moving, instantaneous velocities of individual particles
could be sustained (Figure 9A–B; See Movies S2 and S3) or
fluctuate widely (Figure 9D–F; Movies S2 and S4). Motile double-
label particles occasionally paused for long periods (24 sec) before
resuming rapid movement (Table S1 and Figure S8A and Movie
S4). Motile APP compartments sometimes changed shape during
movement, adopting an elongated tubular shape while the VP26-
GFP particle remained the same size, consistent with the
interpretation that these GFP particles represent single capsids
(Figure S8B; See Movie S5).
Live imaging of cells double-transfected with VP26-GFP and
APP-mRFP and then infected with the gEnull virus demonstrated
the same pattern seen by immuno-fluorescence (Movie S6).
Cytoplasmic viral particles labeled with VP26-GFP did co-localize
with APP in the nuclear area, while few viral particles were found
in the peripheral cytoplasm. Little directed movement of single-
labeled particles was seen, and rapid movements of double-labeled
particles were also rare. Taken in the context of a requirement for
gE in axonal transport of HSV1 and for accumulation of virus at
the periphery of epithelial cells [20,44,45,55,56,57,58], and of our
results in fixed epithelial cells infected with gEnull virus reported
here, these live cell observations suggest a potential role for gE in
viral transport within epithelial cells.
Evidence for a specific interaction of HSV1 capsids with
APP
We also tested the specificity of APP-capsid interactions by
probing for another Golgi-enriched cellular protein, TGN46
[59]. If membranes containing APP randomly encountered
capsids while passing through the trans-Golgi network, then we
expected membranes with TGN46 would also meet capsids with
similar frequency. Random co-localizations of APP, TGN46 and
other secretory cellular proteins with nascent virus might occur
in the trans-Golgi network where transport vesicles emerge for
transit to the cell surface [15,32,60,61,62,63,64], since both
cellular and viral glycoproteins pass through the Golgi apparatus
for synthesis [65,66]. Recent evidence that large particles such
as chylomicrons also meet trans-Golgi membranes for transport
implicates protein kinase D and a natural cellular secretory
process in the packaging and transport of large viral capsids
[67].
As for APP, TGN46 also moved from its normal peri-nuclear
location to become distributed throughout the cytoplasm by 7 hr
Figure 8. Co-transport of VP26-GFP particles and APP-mRFP in live cells. (A) The first frame of a video sequence captured at 7–9 hr p.i.
captured at 3-sec intervals for 900 sec (15 min). Many (64%) VP26-GFP particles (green) co-localize with APP-mRFP compartments (red) in this frame
appearing bright yellow (arrows). VP26-GFP particles travel with APP-mRFP vesicles, and sometimes join and separate from APP. White lines show the
boundaries between cells and position of the nuclei (N). Also see Movie S2. (B) Tracings of some VP26-GFP particles moving with APP-mRFP. Traces
are pseudocolored for ease of visualization. Dots and arrowheads indicate the beginning and end of movements, respectively. (C–D) Microtubules are
in disarray in HSV1-infected cells. (C) Example of mock-infected and (D) VP26-GFP HSV1 infected cells stained for b-tubulin (red) and DAPI (blue) at 7–
9 hr p.i. and imaged by laser scanning confocal. See also Figure S7. (E) Histogram of the instantaneous velocities in infected cells of dual VP26-GFP-
APP, solo VP26-GFP and solo APP only particles. Instantaneous velocities of VP26-GFP-APP (n=118), solo VP26-GFP (n=15) and solo APP (n=64)
particles in 20 cells in 6 experiments were measured. (F) Table of movements. Quantitative comparison of average instantaneous velocity, maximum
velocity and frequency of moves (% motile) for each type of particle from 3–5 different cells from 3 independent experiments, where n= number
particles measured. Note the decreased frequency of movements of the VP26-GFP particles without APP-mRFP, third column. See also Movie S2,
Figure S7 and S8, and Table S1.
doi:10.1371/journal.pone.0017966.g008
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VP26-GFP particles appeared inside larger TGN46-staining
structures that also stained for APP (Figure 10C and D).
Quantitative analysis revealed that the majority of peri-nuclear
VP26-GFP particles co-localized with both TGN46 and APP
(53.269.8%), and fewer with APP alone (27.468.2%) (Figure 10D
and G). Intensity profiling showed co-alignment on a pixel-wise
basis of all three fluorescent particles in the peri-nuclear region
(Fig. 10F).
In sharp contrast, in the peripheral cytoplasm many VP26-GFP
particles co-localized with APP but very few also had TGN46
staining (Figure 10C and E). At these more peripheral locations,
only 25.567.5% of VP26-GFP particles co-localized with both
TGN46 and APP, while 64.768.8% co-localized with APP alone
(Figure 10E and H). Notably no VP26-GFP particles in either
location were found to co-localize with TGN46 alone. These data
are explained if interplay between capsid and APP is not random,
is more robust than with TGN46, and if Golgi elements were able
to maintain some level of sorting of transport vesicle proteins
despite viral occupants.
At slightly later times (9 hr p.i.) the large triple-labeled clusters
in the Golgi region seen at 7 hr p.i. were less pronounced, and
some appeared to have drifted outwards to the intermediate
cytoplasm. This change may reflect the fragmentation of the Golgi
that occurs in HSV1-infected Vero cells [48,68]; the re-
organization of microtubules shown here and reported elsewhere
[54,69]; and the redistribution of the trans-Golgi network marker,
TGN46, reported to occur in confluent epithelial cell cultures after
12 hr of continuous exposure to herpes virus [50,70]. This
fragmentation of the Golgi and reorganization of the microtubules
induced by HSV1 infection affects the critical location of APP.
Interactions of viral particles with APP-containing membrane
systems may contribute to Golgi fragmentation and microtubule
instability, possibly by altering the distribution and/or function of
the cellular transport machinery and its various cargos.
Discussion
By synchronizing infection and performing live imaging of
VP26-GFP-labeled capsids in cells expressing fluorescently labeled
APP, we report results that provide new insights into the
interaction between viral and host cell components during transit
of virus to the surface. Functional relevance to the virus of
interplay with APP, an identified motor receptor, is clear:
association of viral capsids with membrane systems containing
APP confers a propensity to move through the cytoplasm at fast-
anterograde transport rates. Riding on or entering cellular
membrane systems that normally traffic to the surface would thus
promote efficient viral egress. By coordinating secondary envel-
opment with acquisition of the cellular vesicular transport
machinery, the virus would be assured of reaching the cell surface
in an infectious form.
In summary, the evidence includes: (1) VP26-GFP-labeled
particles in the cytoplasm are frequently found together with both
viral glycoproteins and cellular APP; (2) VP26-GFP-labeled
particles travel together with APP for long, rapid trajectories,
and GFP particles lacking APP move less often; (3) Co-localization
with APP is specific, since GFP-labeled capsids and viral
glycoproteins were less frequently found with other cellular
organelle membrane proteins, LAMP2 and TGN46; (4) gEnull
particles stain for APP, and siRNA knock-down of APP abolishes
staining; and (5) VP26-GFP particles sustain co-localization with
APP-mRFP throughout transport, while by immuno-fluorescence
co-localization of VP26-GFP with TGN46 is lost. Thus sorting of
cargo is preserved in HSV1 infected cells at least at these time
points after infection, and VP26-GFP-labeled particles appear to
interact with a select APP-containing Golgi-derived membrane
compartment.
Interaction of viral particles with APP-containing membranes is
not without functional consequence: APP-mRFP particles travel
more slowly in infected than in un-infected cells, even without
detectible viral cargo, and APP is mis-localized in HSV1-infected
cells. Such mis-localization could contribute to increased APP
proteolysis with HSV1 infection [37] and lead to additional, as yet
unrecognized, HSV1-induced cellular injury.
Collectively, our results provide new information about
dynamic interactions between nascent viral particles and cellular
membranes, the molecular composition of virus during outbound
transport, and suggest how secondary envelopment and transport
to the surface may be coordinated. Such dynamic interactions
between APP and HSV1 suggest a mechanistic basis for the
observed clinical relationship between HSV1 seropositivity and
risk of Alzheimer’s disease [71].
Synchronization of infection improves identification of
out-going viral particles
By synchronizing infection we minimized viral re-entry during
replication, ensuring that at later time points during productive
infections, .90% of cytoplasmic viral particles are progeny
undergoing outbound transport. Other methods to synchronize
infections include the use of mutant viruses, temperature shifts,
and pharmacologic interference with synthetic pathways [67]. We
chose here to apply a natural, non-mutation or drug-based method
to synchronize infection so as to interfere as little as possible with
the basic, as yet unknown, mechanisms for packaging and
transport. Thus hopefully these methods will also enable future
discovery of molecules that differ between in-coming and out-
going virus under natural conditions.
Outgoing capsids travel with APP
Models for the location of envelopment and the molecular
composition of viral particles transporting to the cell surface are
quite varied and a topic of considerable debate. Two possibilities
for capsid transport are proposed: independent or membrane-
associated (see diagram, Figure 11). In our model, as demonstrated
here, we observe the following: At early time points during viral
production, VP26-GFP labeled capsids recruit APP during
secondary envelopment from cellular membrane systems, princi-
pally the trans Golgi network, and possibly also recycling
Figure 9. Representative movements of dual APP-mRFP and VP26-GFP particles. (A) A double labeled GFP-mRFP particle moves away
from the nucleus (arrow, from Movie S2 shown in Figure 5B, particle 1). The last panel shows 8 frames superimposed to demonstrate the pathway.
See Movie S3. (B, C) Plots of velocity (B) and distance (C) versus time of particle 1 (in A). (D) A GFP-mRFP particle (arrow, from the video shown in
Figure 5B, particle 2) moving away from the nucleus and ending at the periphery of the cell. Last panel shows 23 frames from a time-lapse sequence
captured at 3-sec intervals (selected from a total of 141 frames of a 420 sec video) superimposed to demonstrate the pathway. The particle moves
back and forth and along multiple tracks, and changes its shape during the movement. Circles indicate stationary GFP particles lacking APP-mRFP.
See Movie S4. (E, F) Plots of velocity (E) and distance (F) versus time of particle 2 (in D), show the properties of the movements of each particle.
Instantaneous velocity varies widely, with fast and slow velocities alternating.
doi:10.1371/journal.pone.0017966.g009
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Evidence for specific APP-HSV1 interactions. (A) Uninfected cells stained for TGN46 (red) show compact tufts on one side of the DAPI-stained
nuclei (blue). (B) Cells synchronously infected with VP26-GFP HSV1 (green), fixed and stained for TGN46 (red) and DAPI for nuclei (blue). (C) Higher
magnification of an example of cell infected with VP26-GFP-HSV1 (green) fixed at 7 h p.i. and stained for TGN46 (blue) and APP (red). (D) Co-
localization in the peri-nuclear region shown at high magnification of boxed region "D" in cell shown in (C). Arrows indicate co-localization of VP26-
GFP particles with APP in a TGN46-stained compartment. White arrowhead indicates a VP26-GFP particle apparently on the surface of a TGN46-
stained vesicle. Yellow and cyan arrowheads indicate examples of single anti-APP-stained and both APP and TGN46 stained particles, respectively. (E)
Loss of co-localization at the periphery is shown at high magnification of boxed region E at the periphery of the cell shown in (C). Pink and white
arrows indicate co-localization of VP26-GFP HSV1 with APP alone at the periphery and in the cytoplasm close to the periphery, respectively. Yellow
and cyan arrowheads indicate examples of single APP and both APP and TGN46 labels, respectively. (F) Linescan intensity profile of a region in the
intermediate cytoplasm as seen in (C) shows both coincident (arrows) and non-coincident (arrowheads) peaks of TGN46 staining (blue line) with APP
(red) and VP26-GFP particles (green). (G) Histogram of particles in the peri-nuclear region showing the percentage of VP26-GFP particles that co-
localized with APP and TGN46. The majority of VP26-GFP particles co-localized with APP and TGN46 (51.869.5%) and fewer co-localized only with
TGN46 without APP (11.663.1%). (H) Histogram of particles in the periphery showing the percentage of VP26-GFP particles that co-localized with APP
and TGN46. None co-localized with TGN46 alone, although 25.5614.2% were co-localized with both APP and TGN46. Note that many fewer particles
co-localized with TGN46 in the periphery than in the peri-nuclear region, suggesting that membrane compartments co-localized with viral products
retain the ability to sort their components. N=10 cells, 3,782 particles from three experiments.
doi:10.1371/journal.pone.0017966.g010
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time points after infection. Others have reported that entry of
capsids into the apical side of the TGN may follow the alternate
pathway for trafficking of large particles such as procollagen and
chylomicrons [67]. The budding of alpha herpesvirus into cellular
membrane systems may be similar to mechanisms by which
cellular vesicles enter into multivesicular bodies via ESCRT
proteins [72]. Indeed, isolated enveloped virus contained within a
second cellular-derived membrane transports on microtubules in
vitro [73].
In our videos it sometimes also appears that the VP26-GFP
particle is riding on the cytoplasmic surface of cellular membranes
that are undergoing transport. These ideas as well as other possible
transport configurations are diagrammed in Figure 11.
Budding into dynamic vesicles may be critical for nascent viral
particles to acquire anterograde motors, such as the kinesins, for
transport to the surface. When co-localized with an APP
membrane, VP26-GFP particles moved significantly more fre-
quently and at higher velocities. Thus our live imaging of cellular
APP and viral capsid reveals a functional link between them: APP-
containing membrane alliance confers efficient motility to the
virus.
Evidence for non-enveloped transport
Evidence that the other model of non-membrane-associated
transport occurs is also presented here (see Figure 11)
[4,6,10,18,20,43,74,75,76]. VP26-GFP particles traveled both
with and without APP, although those without detectible APP
were in the minority at the early time points after infection
reported here. Thus capsid/tegument complexes may interact
directly with cellular motors during egress as they do upon
entering the cell [77,78]. Our previous work showed that capsid-
tegument complexes isolated by detergent treatment of infectious
particles transport uniquely retrograde when injected into the
squid giant axon [79]. Since then the tegument components
involved were elegantly identified in in vitro motility assays [80] and
later found to bind both plus- and minus-end directed motors in
reconstitution assays [78].
Reorganization of microtubules in HSV1-infected cells must
play a large role in these two mechanisms of viral transport. We
show here that the microtubule organizing center (MTOC) is lost
in infected Vero cells, and microtubules project from the full
circumference of the nucleus as has been previous described
[54,68]. This reorganization may in part be due to ICP0, a viral
protein that dismantles the microtubule network independent of
infection, inducing coarse nets of aggregated tubules [81].
At later stages, the large triple-labeled clusters of capsid-
envelope-APP, initially found in the peri-nuclear region, became
less pronounced and some clusters appear to move outwards to the
intermediate cytoplasm, probably a consequence of microtubule
reorganization. Thus as productive infection proceeds, capsids
must travel farther after exiting the nucleus to reach membrane
compartments for envelopment. This observation indirectly
supports a necessary role for membrane-free capsid transport
from the nucleus to cortical membrane compartments for
envelopment. Reorganization of the microtubules may allow
Figure 11. Diagram. A cartoon showing various types of interactions between cellular APP and VP26-GFP labeled viral particles documented here.
(A) In the peri-nuclear region, VP26-GFP particles dance around and within large peri-nuclear compartments co-localizedd with viral envelope
proteins, gE and gD, and cellular membrane proteins, LAMP2, TGN46 and APP. LAMP2 compartments separate from this apparent Golgi network early
and rarely co-localize with viral components at the periphery. Some membrane systems with VP26-GFP also label for both APP and TGN46, primarily
near the nucleus at the time points studied here. (B) TGN46 particles separate from VP26-GFP labeled viral components farther towards the periphery,
while the APP particles remain with VP26-GFP particles and with viral envelope glycoproteins, gE and gD, en route towards the cell surface. (C) VP26-
GFP particles may enter smaller post-Golgi APP-staining particles that undergo directed transport. (D) Some VP26-GFP particles remain separate from
APP after leaving the nucleus. These may be inside unlabelled membrane systems or be free in the cytoplasm, some have the capacity to transport
without APP. (E) VP26-GFP particles may ride on the cytoplasmic surface of APP-labeled membrane systems, come on or off these membranes, or bud
into them. Any particular viral particle may employ all of these mechanisms during transit in the cytoplasm. In each case, we hypothesize that
microtubule motors, such as kinesin, are recruited, possibly via APP or another cellular motor receptor.
doi:10.1371/journal.pone.0017966.g011
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blies from the perinucleay area to the cortical Golgi at late time
points of productive infections in epithelial cells.
Intracellular versus extracellular virus
Our data show APP-containing membranes travel together with
intracellular HSV1 particles, and contrast with a failure of mass
spectroscopy to detect APP in preparations of extracellular HSV1
virions [23]. What might be the basis for this discrepancy? One
obvious difference is the type of particle studied: intracellular viral
particles versus extracellular virus. Thus HSV1 may lose APP
membranes upon release from the cell, as would happen if APP
were in a second cellular membrane encircling intracellular viral
particles and not in the viral envelope. Indeed, such a second
membrane was found in our study here, and has been elegantly
shown by electron-microscopy of both intracellular HSV1 and
PRV, a related alpha herpesvirus [9,15].
How HSV1 travels outwards in epithelial cells
Synthesizing our results with the work of others, we propose
various models for coordination of capsid envelopment and
transport to the cell surface after emergence from the nucleus
(Figure 11). In one scenario, capsids exiting the nucleus at early
time points after viral replication meet Golgi elements in the peri-
nuclear region, where both viral and cellular membrane proteins
are glycosylated. Capsids would thus acquire envelope by
budding into Golgi compartments and entering cellular com-
partments whose membranes contain APP, a vesicular motor
receptor that binds kinesin-1 [82] and drives anterograde
transport [27]. Alternatively, nascent capsids may enter cellular
transport vesicles in the trans-Golgi network or even during their
transit through intermediate cytoplasm. Capsids lacking APP may
be either naked in the cytoplasm, complexed with tegument, or
associated with an unlabeled membrane compartment. Since
some of these move, they must have alternative mechanisms to
attract motors, such as tegument recruitment of kinesin and
dynein [78]. Finally, nascent viral particles may ride on transport
vesicles, possibly also coming in and out of the vesicle en route to
the synapse or cell surface.
A role for HSV1 in APP dynamics
Emerging epidemiological evidence links cognitive impairment
with peaks in anti-HSV1 antibody titers in human serum [71].
More recently, chronic active HSV1 infection in the central
nervous system has been reported [83], lending additional
credence to the idea that chronic active CNS infection may last
late in life undetected, causing progressive damage. Correlations at
the molecular level between genes associated with AD and cellular
proteins involved in HSV1 infection are described, although direct
experimental evidence is still lacking [84]. Here we show that
HSV1-infected cells display abnormal APP distribution, and APP
and HSV1 capsids co-localize and travel together within cells,
apparently by fast anterograde transport mechanisms. Thus
cellular APP is affected by HSV1 infection–its distribution, its
dynamic movements, and possibly its post-translational modifica-
tions, including phosphorylations and proteolysis [37]. HSV1
DNA is found in senile plaques [85]. While a role for HSV1 in AD
remains controversial, the notion is especially intriguing since
HSV1 infection offers a potentially treatable target.
Once inside the neuron, HSV1 enters a latent stage that persists
for the lifetime of the host. Decline in immunity associated with
aging {Arlt, 2004 #292;Kurz, 2004 #291} increases chronic
reactivation of herpesvirus [86]. Once A-beta has accumulated
beyond a particular point, removal becomes difficult and repeated
deposition results in more, larger plaques. Circulatory changes
with decreasing perfusion, also correlated with aging, would
compound this problem, since A-beta is digested and removed by
serum enzymes. Reactivation of virus results in the recurrent
"cold" sore on the lip. Such long-term chronic infection may not
be benign. Since the concept of slow viral disease first proposed by
Gajdusek [87], many examples have been found. Famous among
these are HPV [88], HIV [89], as well as another member of the
herpesvirus family, Epstein-Barr virus [90]. Hence the question is
not whether HSV1 causes neurological damage, but rather how
significant that damage is over a lifetime. Nascent virus induces a
profound alteration in cellular membrane organization and
anterograde transport, subcellular systems known to be required
for neuronal function and survival. The interactions of HSV1 with
APP shown here suggest a molecular mechanism for the observed
epidemiological correlation: long-term chronic active HSV1
infection would affect APP distribution, expression and processing,
and thereby have significantly more impact than previously
considered.
Materials and Methods
Virus and cell culture
VP26-GFP HSV1 was a gift from Dr. Prashant Desai (Johns
Hopkins University) [28]. VP26-GFP HSV1 expresses green
fluorescent protein (GFP)-fused inside the first 4 amino acids at the
N-terminus of UL35 (VP26), a 12 kDa minor capsid protein
[29,30]. Viral strains with the gE gene knocked out, the parent
strain (NS) and a strain created from the gE null with the viral
gene replaced, were obtained from Harvey Friedman [45,91] and
the knock-out gene replacement confirmed by sequencing after
propagation in the Bearer lab. Vero, HELA, and ARPE-19 cells
(ATCC) were cultured on glass coverslips or chambered glass
coverslips (Lab-TeK) in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum and used for
25 passages.
Virus was isolated as described [79]. Basically, confluent Vero
cells are infected with a viral stock at ,1–10 MOI and
incubated at 37uC. Cells are harvested when they began to
round (16–17 hr p.i.) by scraping together into the media,
transferred to a 50 ml sterile tube and freeze-thawed 3 times by
passing the tube from dry ice-ethanol (278uC) to 37uCw a t e r
bath. Viral particles in the cytoplasm are released from cells by
low-energy sonication (Fisher Scientific 550 Sonic Dismembra-
tor) set at 3.5 for 10–15 sec. The viral solution is then
centrifuged for 10 min at 2000 rpm (10006g) in an IEC
serofuge at 4uC to remove nuclei and cellular debris. After
filtration through a 0.45 mm Millipore filter, the supernatant is
layered over a discontinuous sucrose gradient (3 ml of 10%, 8 ml
30%, 8 ml 60% in PBS) in 38.5 ml disposable centrifuge tubes
for the SW28 rotor (Beckman) and centrifuged for 2 hr at
25,000 rpm (80,0006g). The lower fuzzy white band, just above
the 60–30% sucrose interface, is collected (2–3 ml), transferred
to a fresh centrifuge tube and diluted to 30 ml with PBS. Diluted
virus is centrifuged again at 25,000 rpm in the SW28 rotor for
1.5 hr at 4uC, the resultant pellet layered with 150 ml of PBS and
left overnight to resuspend without mechanical mixing. The
150 ml viral suspension is then aliquoted, drop-frozen in liquid
nitrogen and stored at 280uC. This yields viral preparations
with 2–30610
9 pfu/ml and genome/pfu ratios of 23–98 without
and 2.5–46 with DNAse treatment using the protocol described
in [31], and also see below. Negative-stain electron-microscopy
demonstrated that 49–50% of viral particles retain viral
envelopes as we previously described [17,79].
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The number of viral genomes was determined in parallel by
quantitative PCR both with and without DNAse treatment, using
the gB primers as described [31]. Briefly 2 ul of gradient-purified
virus is mixed with 400 mlo f1 6 reaction buffer (10 x DNase 1
reaction buffer: 100 mM Tris-HCl, pH 7.5, 10 mM MgCl2 5m M
CaCl2 (Ambion)) and then split into two 200 ml aliquots. One
aliquot is treated with 2.5 ml of DNase1 (5 units: Abgene
recombinant DNase 1, Thermofisher AB) and both tubes
incubated at 37uC for 30 min and then at 75uC for 10 min. After
incubation, 2.5 ml (25 mg total) salmon sperm DNA (Invitrogen) is
added to each tube. DNA is then extracted with Qiagen mini kit
for a final volume of 200 ml. Samples are then diluted 1:10
23 and
1:10
24 in reaction buffer producing a DNA preparation ready for
PCR quantification.
Quantification was determined by comparison of the DNA from
our viral prep to known concentrations of genomes obtained
commercially for clinical studies, HSV1 Type 1 DNA Macintyre
strain (Advanced Biotechnologies Inc.) run in parallel. Viral preps
and these standards with and without DNAse treatment are mixed
with 12.5 ml SYBR Green Master Mix (Applied Biosystems Inc),
25 mM of each forward and reverse sense primer and 5 mlo f
diH2O. Primers were selected from the HSV1 glycoprotein B, an
essential gene. The forward sense primer is 59-CCA CGA GAC
CGA CAT GGA GC-39 and reverse primer 59-GTG CTY GGT
GTG CGA CCC CTC-39 [25] resulting in a predicted 246 base-
pair product from HSV1 viral genomes according to the database
of HSV1 F-strain, NCBI Ass. Number GU734771.1. After one
cycle of denaturation (95uC for 10 min), 40 cycles of amplification
are performed (95uC 10 s and 60uC for 1 min). During each 60uC
phase fluorescence is measured and from this data the DNA
concentrations are calculated against a standard curve generated
from the series of dilutions of known viral copy numbers run in
parallel.
To determine plaque-forming units, viral preparations were
titered in triplicate by infecting confluent Vero cells under
synchronizing conditions. Vero cells were plated at 0.5610
6 cells
per 6-well plate and incubated overnight at 1.5610
6 confluent
cells per well after division. Gradient-purified virus was serially
diluted in growth media (1/100 to 1/10
28 viral preparation/
media). Each viral dilution (0.5 ml) was inoculated into three wells
of confluent cells on ice. After an hour cultures were warmed to
37uC and incubated another hour and then rinsed in acid-glycine
according to the synchronization protocol (below). To limit
subsequent infection through the media, cultures were overlaid
with 0.5% agarose in growth media plus 1% human serum
(Gibco/invitrogen) after the acid-glycine rinse. Thus virus has 1 hr
to enter cells. Cultures were incubated at 37uC for 2–3 days when
plaques become distinctly visible.
Plasmids
A pMonoRed-APP695 plasmid encoding MonoRed (mRFP)-
tagged 695-aa human APP (APP695) was generated from a
backbone plasmid, pEGFP-N3/VP16 [79], by replacing GFP with
mRFP amplified from mRFP1-pRSET-b plasmid (from Dr. Roger
Tsien) [92] and replacing VP16 with APP695 from the APP-YFP-
coding domain in pShuttleCMV plasmid (from Drs. E.-M.
Mandelkow and Jacek Biernat, Max Planck Institute, Hamburg,
Germany) [53]. MonoRed (mRFP1) sequence was amplified by
PCR using BamHI forward, 59-CGGGATCCATGGCCTC-
CTCCGAGGAC-39; NotI Reverse, 59-TTGCGGCCGCTTA-
GGCGCCGGTGGAGTG-39 primers and ligated between the
BamH1/Not1 site in pEGFP-N3/VP16. This generated a new
plasmid, pVP16-MonoRed, with mRFP at the carboxyl terminus of
VP16. APP695 was amplified from human APP-YFP in pShut-
tleCMV with the primers: HindIII Forward, 59-GCAAGCT-
TATGCTGCCCGGTTTG-39; SacII Reverse, 59-CGCCGCG-
GGGTTCTGCATCTGCTCAAAGA-39 and ligated between the
HindIII/SacII sites in pVP16-MonoRed. Thus, mRFP tag is
located 18 nucleotides (CCC GCG GGC CCG GGA TCC) from
the last nucleotide coding the COOH terminus of APP. Expression
from this plasmid is driven by the CMV promoter. The sequence of
APP695 in pMonoRed-APP695 plasmid was verified. The VP26-
GFP plasmid, pK26GFP, was obtained from Desai [28]. Expression
from this plasmid is driven by UL35 promoter.
Natural Synchronization of Viral infection
To synchronize viral infection, subconfluent cultures were first
chilled on ice for 30 min-1 hr and then inoculated with VP26-GFP
HSV1 virus, typically diluted to a viral concentration of 10 plaque-
forming units per cell, i.e.10 MOI. We used subconfluent
monolayers because our live video experiments had revealed viral
particles passing through junctions between cells in confluent
cultures (Bearer and Ferland, MS in preparation). Because our
goal was to create culture conditions that limited in-coming virus
without resorting to genetic manipulation of the virus or
pharmacologic intervention, we used sub-confluent monolayers
to reduce such junctional transfer of virus between cells, and short
(1 hr) infection times. Even at 10 MOI with a 2.5 genome/PFU
ratio, this did not result in infection of all cells. We accepted this
lower infection efficiency in favor of better assurance that the
possibility of in-coming virus at later time points was eliminated to
the extent possible. Even though the virus was titered under
synchronizing conditions, that titering requires confluent mono-
layers, where each virion has a better chance of encountering a
cell. In subconfluent cultures, with cells not touching each other,
virions also fall between cells necessitating higher viral MOIs for
efficient infection rates.
After inoculation, cells were incubated on ice for another
30 min-1 hr to allow virus to adhere, and then warmed to 37uCt o
allow viral entry. After 1 hr infected cells were washed with acid
glycine for 3 min at RT (0.14 M NaCl, 5 mM KCl, 1 mM
MgCl2-6H2O, 0.7 mM CaCl-2 H2O, 0.1 M glycine, [pH 3]) [93]
to remove adherent virus and any viral particles in the media. Low
pH is reported to bypass the gD-inhibition and drive virus into
cells in a gD independent manner [94,95,96]. To prevent re-entry
of emerging virus later in infection and block any residual virus
remaining in the culture from initial inoculations, 1% human
serum, containing anti-HSV1 antibodies that neutralize extracel-
lular virus, was added [97]. To our knowledge, we are the first to
use this combination of low temperature inoculation to maximize
virus-cell adhesion without internalization, low pH wash to induce
simultaneous entry or release of adherent virus, and neutralizing
antibodies to control the timing of infection. The infected cells
were then fixed at 6, 7 and 9.5 hr p.i. and stained with DAPI. For
quantification, images of fields of infected and mock-infected cells
were randomly selected. We used widefield for a comprehensive
picture of the full-thickness of the cell. The flatness of Vero cells
allowed us to focus on capsids throughout the cytoplasm with
wide-field illumination. From the collected images, 16,300 capsids
from 165 infected cells were counted and categorized according to
number and location, cytoplasmic or nuclear. We did not attempt
to quantify nuclei with more than 10 capsids as the GFP
fluorescence demonstrated that these were clearly highly produc-
tive of viral particles. GFP particles in the cytoplasm were clearly
distinguishable from aggregates and rare GFP debris as capsids
have a uniform size (See Figure S2).
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Cells on coverslips were washed in serum-free media and fixed
for 15 min in 4% paraformaldehyde in PBS. For microtubule
staining, cells were fixed in 220uC methanol for 5 min. The
following antibodies were used: rabbit anti-peptide antibody
against APP C-terminus aa676–695 of APP695 (1:2000, protein
A purified IgG, 14 mg/ml Sigma A8717) or N-terminus aa46–60
of APP695 (1:500, protein A purified IgG, 8.1 mg/ml, Sigma,
A8967), amino acids); anti–APP-C aa673–695 of APP 695
(1:1000, 0.25 mg/ml, affinity purified on the peptide, Zymed/
Invitrogen 36–6900); mouse anti-VP5 antibody (IgG2b, 1:1000,
3B6, EastCoast Bio); mouse anti-gE antibody (IgG2a at 1:1000,
East Coast Bio); mouse anti-gD antibody (IgG2a,1:1000, East
Coast Bio); mouse anti-LAMP2 (IgG1, 1:200, Abcam); mouse anti-
tubulin (IgG1, 1:400, Sigma); sheep anti-TGN46 (1:1000, AbD
Serotec); rabbit anti-histone H3 (1:200, protein A purified IgG,
0.9 mg/ml goat anti-rabbit IgG (Upstate Biologicals-Millipore);
mouse anti-actin (1:1000, Amersham/GE Healthcare) goat anti-
rabbit Alexa-Fluor 555 (1:2000, Molecular Probes); donkey anti-
rabbit IgG Alexa-Fluor 555, donkey anti-sheep IgG Alexa-Fluor
647 and goat anti-mouse IgG Alexa-Fluor 647 (1:2000, Molecular
Probes); goat anti-mouse Cy5 (IgG2b, 1:500, Jackson Labs); goat
anti-mouse FITC (IgG2a, 1:2000, Jackson Labs).
To minimize non-specific binding of antibodies from rabbit and
sheep to viral Fc receptor, gE/gI [42,98], we used a blocking
buffer containing 20 mg/ml human IgG (Sigma), 3% BSA, 3%
normal goat serum and 0.2% Triton X-100 in PBS (pH 7.4). For
TGN46 staining, goat serum was omitted from the blocking buffer
and the concentration of human IgG raised to 40 mg/ml. After
blocking, cells were incubated for 1 hr in primary antibodies
diluted in 3% BSA and 0.2% Triton X-100. After three washes in
PBS, cells were incubated in secondary antibodies, washed in PBS
and mounted in anti-quench with DAPI (0.001%) [99]. Non-
specific staining by the secondary antibodies was monitored by
omission of the primary antibodies in coverslips stained in parallel
and then using the exposure times for stained samples that gave no
signal in the secondary-only sample. Neither anti-gE nor anti-gD
antibody stained mock-infected Vero cells. A Blast search (NCBI,
NIH), found no HSV1 proteins with amino acid sequence
homology to APP peptide antigens.
Fluorescence images were captured either by a 63X/1.4 N.A.
oil immersion Plan Apochrome objective on a Zeiss Axioscope Z1
using the MRM AxioCam and AxioVision 4.5 software, or on a
Zeiss LSM 410 confocal laser scanning microscope equipped with
a krypton-argon laser for excitation at 488, 568, and 647 nm
running Phoenix, v,2,0,2524 software. (Microcosm, Inc.). Confocal
images of fixed cells used a pinhole adjusted to a narrow optical
section (0.8 mm). Capture time was set by imaging coverslips
stained in parallel with secondary only, and using linear grayscale
for each channel. Figures were created using Photoshop CS2 and
3 (Adobe). For widefield deconvolution a z-stack was collected at
0.375 nm stepsize with 45 focal planes using th 63x objective. A
region of interest was selected and deconvolved using AxioVision
4.5 DCI program using the automated PSF and interative
processing. Deconvolved stacks were projected into 3D and
rotated using AxioVision 4D Rendering software (Zeiss.com).
Western blotting
After 9 hr, synchronously infected or mock-infected cell cultures
(100 mm petri dish) were washed in warm serum-free media, and
then scraped into lysis buffer (50 mM NaCl, 30 mM Tris-HCl
(pH 7.2), 5 mM EDTA, 50 mM NaF, 2 mM sodium vandadate,
1 mM PMSF, 5 mM p-nitrophenylphosphate, 1% Nonidet-p-40),
protein concentration measured by bicinchoninic acid kit (Sigma
Aldritch), and volume adjusted to give equal protein concentra-
tions across all samples which were then aliquoted into gel sample
buffer and boiled for 5 min [79]. Parallel lanes of 10%
polyacrylamide gels (BioRad) were loaded with equal total protein
concentrations of HSV1 infected and mock-infected cell lysate and
electrophoresed. Viral preparations were similarly loaded and run
in 7.5% SDS gels. After overnight transfer in transfer buffer [17],
blots were either stained for protein with amido black in methanol
(Sigma) or blocked in Tris-buffered saline with 0.2% Tween and
5% instant milk, and probed for c-APP with anti-APP rabbit
polyclonals (Zymed, Sigma, and Chemicon); for actin with anti-
actin mouse monoclonal (Amersham) as a loading control; and for
VP5, a 150 kDa abundant capsid protein (Virusys/Invitrogen) to
detect the presence of virus. Banding patterns were detected by
HRP-conjugated goat anti-rabbit-antibody or anti-mouse (Calbio-
chem) developed for enhanced chemiluminescence (Amersham/
GE Healthcare) according to the manufacturer’s instructions, with
exposure to Kodak Xray films for 1, 5, 10, 20 min and over night.
The position of the blot on the film was marked with black lab
pen. Films were developed in a Kodak X-OMAT automated film
processor. After developing, the film was placed on the
nitrocellulose and the position of the pre-stained molecular weight
markers indicated on the film. None of the antibodies used in this
study detected new bands in HSV1 infected cells compared to
uninfected cells. Detection of increased APP expression was
variable, and best detected when protein concentrations were
measured and equivalent amounts loaded from uninfected and
infected cells.
Quantitative analysis of co-localization
Quantitative co-localization analysis was performed on raw data
using AxioVision 4.5 software in two ways: (1) Scatter plot, a
graphical display that compares total pixel coincidence between
two channels across the entire image. The intensities of two
channels are distributed along the x- and y-axis in a scatter plot. If
intensity of images in each channel completely overlaps, then the
plot displays a straight diagonal lin,e starting from the origin of the
scatter plot. This computational approach provides an average
pixel-coincidence between two channels of the same field. (2)
Linescan showsw a graph of the pixel intensity in each channel
versus its position along a straight line drawn across a merged
image. A superimposition of peaks between channels indicates
high intensity overlap per pixel along the line. Linescans detect
overlap along a line in a region of interest, while scatterplots can
measure the global degree of co-incident intensities across a whole
image field.
The number of fluorescent particles was counted in randomly
selected images of synchronously infected cells by an independent
person. All results are presented as mean 6 standard error of the
mean (SEM). Histograms were made from spreadsheets of counts
using Microsoft Office Excel.
Immunogold Electron-microscopy
Synchronously HSV1-infected Vero cell cultures were washed
in warm serum-free media and fixed in 4% formaldehyde in
100 mM phosphate buffer overnight. Fixed cells were rinsed in
PBS containing 0.15% glycine, and then scraped into PBS
containing 5% bovine serum albumin using custom-made Teflon
scrapers prepared from Teflon sheets. Scrapings were pelleted in
an Eppendorf benchtop centrifuge, resuspended in warm PBS
with 10% gelatin and 0.01% blue dextran (Sigma), re-pelleted, and
cooled to 4uC to solidify the gelatin. The tips of the tubes
containing a visibly blue pellet of cells were cut off, the cell pellets
scooped out and post-fixed in buffered 4% formaldehyde for
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sucrose at 4uC. The next day, cell pellets were mounted onto metal
specimen pins (Leica Microsystems Inc, Deerfield, IL), frozen in
liquid nitrogen and placed in 100% methanol containing 1%
uranyl acetate (SPI Inc) cooled to 280uC in an AFS2 Freeze
Substitution Device (Leica Microsystems, Inc).
The AFS2 was programmed to warm to 260uC over 16 hr after
which time the methanol/uranyl acetate was replaced with pre-
cooled absolute ethanol. The specimen pins were removed from
the solvent leaving the cell pellets to fall to the bottom of the tubes
and the cell pellets were washed six times in fresh, cold ethanol
over 6 hr. The cell pellets were then gradually warmed to 250uC
and infiltrated with increasing amounts of Lowicryl HM20 resin
(Electron Microscopy Sciences, Hatfield, PA) dissolved in ethanol
and left overnight in a 1:3 mixture of ethanol and resin. The next
day, the cells were soaked in 3 changes of 100% Lowicryl resin and
then placed in gelatin embedding capsules for polymerization. The
cell pellets were covered with fresh 100% resin, labeled and
polymerized under UV light at 250uC. After 5 days, the specimen
blocks were gradually warmed to RT overnight.
Polymerized blocks, which were pink in color, were removed
from the embedding capsules and placed overnight under UV
illumination (in a laminar flow cabinet) at RT to allow
unpolymerized volatile resin components to escape. Cells were
sectioned with an Ultracut S ultramicrotome (Leica Microsystems
Inc) equipped with a diamond knife (Diatome USA Inc). Sections
were mounted on Formvar/carbon-coated metal specimen grids.
After blocking with 20 mg/ml human IgG in PBS, sections were
fixed with 1% gluteraldehdye for 10 min, quenched in 1% glycine
in PBS for 10 min, blocked in PBS containing 10% BSA and 0.5%
fish skin gelatin (blocker; Sigma), and then labeled with rabbit anti-
cAPP antibodies (Sigma) or with irrelevant rabbit antibodies
(rabbit anti-mouse IgG, Invitrogen) diluted 1:20 in blocker,
followed by 10 nm protein A-gold also diluted in blocker
(University of Utrecht, The Netherlands). Omitting the human
IgG block had no effect on the level of labeling. After immunogold
staining, sections were contrasted with uranyl acetate and lead
citrate [100]. The immunolabeled, contrasted sections were
imaged using a Tecnai G2 20 transmission electron microscope
operating at 80 kV. Images were collected using a 2 megapixel
side-mounted digital camera (XR41; Advanced Microscopy
Techniques) attached to the TEM.
siRNA knock-down of APP
Three formulations of siRNA were purchased from Qiagen
(Valencia, CA, USA): non-silencing siRNA sequence, shown by
Basic Local Alignment Search Tool (BLAST) search not to share
sequence homology with any known human mRNA; 2) specific
siRNA against an unrelated gene product, MAPK-1, (Qiagen
SI00300755); and specific siRNA against the APP target sequence
CTGGTCTTCAATTACCAAGAA, an experimentally validated
target (Qiagen, SI02780288). Knock-downs were performed
according to the manufacturer’s instructions in ARPE-19 cells
and in Vero cells with minor modifications. Briefly subconfluent
monolayers were grown in 12-well plates to a density of 1.2610
5
cells in 1100 ml of growth media per well. For each well, siRNA
(15 ng in 100 ul optimen (Gibco/BRL/Invitrogen)) was mixed
with 6 ul HiPerfect transfection reagent (Qiagen) and incubated
for 10 min RT before being added to the cells. After removal of
the media from the culture wells, the siRNA mixture was added
(106 ml) to each well and the culture incubated overnight at 37uC.
On day 2, the siRNA media was replaced with growth media and
cultures incubated for another day to achieve optimal silencing by
Western blotting. At 48 hr post-transfection, cultures were
synchronously infected with VP26-GFP HSV1 or mock infected.
At 7–9 hr p.i., cultures were either scraped into Western blot lysis
buffer or fixed, stained for APP, gE or gD and DAPI, and imaged
as described above.
Live confocal imaging
Vero cells were grown on chambered glass coverslips (Lab-Tek,
Nalge Nunc International) and transfected with the pMonoRed-
APP695 plasmid, or with both pMonoRed-APP695 and
pK26GFP for cells infected with the gEnull, gE wildtype (NS) or
gE rescue virus, using 1 mg plasmid DNA/chamber containing
40–80,000 cells using lipofectamine2000/Optimem standard
protocols (Invitrogen). After 48 hr incubation to allow for fusion
protein expression, cells were synchronously infected with VP26-
GFP HSV1 at 1–10 PFU/cell, and either fixed or imaged at 5–
10 hr p.i.. Only cells with low levels of mRFP expression as
determined by weak fluorescent signal, no aggregation of label in
nuclear envelope, and clearly visible small, rapidly motile mRFP
particles, as previously described for YFP-APP transfections [53],
were selected for imaging. Because of variability between cells in a
culture, quantification of expression levels on an individual cell
basis would not be feasible. We did not test for normal
glycosylation of the fusion protein since the APP-mRFP has
almost identical distribution to the endogenous protein, and we
therefore infer that it is normally processed.
Dynamic interactions between APP-mRFP particles and VP26-
GFP-labeled capsids or viral particles were recorded under a 63X/
1.4 N.A. oil objective, and time-lapse image sequences were
collected at 3-second intervals simultaneously in FITC- and Cy3-
fluorescent channels as well as a transmitted light channel, with 3
photo multiplier tubes using a Zeiss 410 confocal laser scanning
microscope as described above. During observation, cells were
maintained at 37uC through a temperature-controlled sample
chamber and ring (Tempcontrol 37-2 digital, Carl Zeiss, Inc.).
Movies from resulting time-lapse series were produced using NIH
ImageJ (NIH).
Cells with low to moderate expression of APP-mRFP were
selected for long-term imaging. Expression levels were determined
by the intensity of the image after scanning at a fixed pinhole (40),
gain (Detector gain: 80–120, Amplifier gain: 1–6) and Detector
offset (3990). Our rationale was to avoid high levels of expression
that could alter normal APP distribution. The large pinhole size
gave an optical section of 12 mm that captured the full cell
thickness. Most particled moved perpendicular to the optical
section and remained within the filed of view. A few particles
released to the apical (dorsal) cell surface remain visible until they
separate from the cell and move out into the media.
Transport analysis
Instantaneous velocity was measured from confocal sequences
of synchronously infected cells using MetaMorph (Molecular
Devices, Inc, Sunnyvale CA, USA). Videos of cells with active
movements were selected for analysis. All mobile VP26-GFP and/
or APP particles were measured inside each cell selected. Briefly,
the distance moved between two consecutive frames was measured
by marking the center of a fluorescent particle in each consecutive
frame with a mouse-driven cursor. The distance in pixels was
converted to real measurements in microns based on calibration
(typically, 1 pixel represented 0.14 mm). To evaluate the accuracy
of cursor marking and stage drift [101], we measured the
movements of viral particles in fixed cells and of stationary viral
particles in live cells from image sequences captured in time-lapse
mode at the interval of 3 sec, as for our living moving particles.
Mean displacements of GFP particles in fixed cells and stationary
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measurements) and 0.2760.09 mm (n=990 measurements),
respectively. Displacements of stationary GFP particles in live
cells reflected our recording condition, and were thus used to set
criteria defining pause versus movement. A normal distribution of
the frame-to-frame displacements corresponding to 95% of the
tracking error distribution (62 SD) gave an interval score from
0.09 to 0.45 mm. Thus, any displacement of viral particles moving
less than 0.45 mm (3 pixels) between consecutive frames was
considered immeasurable. From this, only movements with
instantaneous velocities greater than 0.15 mm/s were designated
as runs and included in velocity calculations. Periods with
instantaneous velocities between 0–0.15 mm/s for at least two
consecutive frames were designated as pauses. Only particles
moving into and out of a frame were counted.
Supporting Information
Figure S1 Quantitative validation of infection protocol.
(A) Distribution of viral particles in infected cells. Cells infected
with VP26-HSV1, incubated for 7–9 hr p.i., fixed and stained for
DAPI as in Figure 1. Numbers of cells in each of five categories
representing distribution of viral particles as diagrammed were
counted from digital images taken at random from 3 different
experiments. After constitutive infection (96.2+/2 6.7% infected,
top row) when virus remains in the medium throughout
incubation, cells displayed GFP-labeled particles in all 5
distribution categories, including 29% that display .10 cytoplas-
mic particles with no evidence of nuclear GFP synthesis. These
GFP particles thus must represent in-coming GFP-labeled virus. In
parallel cultures infected for 1 hr with our protocol (87.5 +/2
24.4% infected, lower row), no cells were found with .10
cytoplasmic GFP-particles in the absence of nuclear GFP (boxed
column), and a higher percentage of cells were found with only
nuclear GFP, or both nuclear GFP and cytoplasmic GFP particles
(lower row). Thus, after synchronized infection only small numbers
of VP26-GFP particles are found in the cytoplasm of cells not
expressing viral genes as evidenced by absence of viral-encoded
VP26-GFP in the nucleus. (B) Average number of VP26-GFP
labeled viral particles in the cytoplasm after synchronization. To
determine the average number of incoming viral particles in the
cytoplasm at later stages of infection, we counted particles at two
time points (6.5–7 hr and 9 hr) after synchronized infection. At
6.5–7 hr p.i., the two predominant patterns in productively
infected cells were: (1) few cytoplasmic VP26-GFP-particles
whether or not there was nuclear GFP (3+/23.0 and 3+/22.3
cytoplasmic particles respectively); or (2) many cytoplasmic
particles in cells with strong nuclear GFP (65+/25 cytoplasmic
particles). Less than 3% of cells displayed other distributions, and
none had many cytoplasmic particles without nuclear GFP. At
9 hr p.i. all infected cells had strong nuclear GFP and many
particles in the cytoplasm. Experiments were done in triplicate and
counts (16,300 GFP particles) were made on at least three different
coverslips for each condition for no less than 10 microscopic fields
per coverslip.
(TIF)
Figure S2 The majority of VP26-GFP cytoplasmic
particles represent viral capsids. (A) Co-localization of
VP26-GFP particles with the VP5 capsid protein in the cytoplasm.
Cells infected with VP26-GFP HSV1 (green) at 7–9 hr p.i. were
fixed and immuno-stained for VP5 (red). Most cytoplasmic
particles appear yellow as they are labeled with both fluoro-
chromes. (B and C) High magnification of the boxed region in (A)
showing the individual channels of VP26-GFP (B, green) and anti-
VP5 (C, red). Of 27 GFP particles, 24 also stain for VP5 in this
region. Arrowheads indicate the few GFP-particles not stained for
VP5. Since VP26 coats the outside of particles after capsidation,
some particles will be expected to stain for VP5 but not yet
acquired VP26-GFP. Conversely, VP26 may mask VP5 antibody-
binding sites. Such particles do not stain consistently with anti-VP5
antibody [31]. For this high level of combined staining, we
modified the fixative to include the detergent 0.2% Triton. This
improved VP5-capsid antibody staining, further suggesting that
viral capsids are inside a detergent-soluble membrane compart-
ment. (D) A linescan showing coincidence of the peaks of pixel
intensity of VP26-GFP and VP5 channels. (E) Histogram of the
percentage of VP26-GFP particles co-localized with VP5. Note
92.862.9% of VP26-GFP cytoplasmic particles (n=2927) co-
localize with VP5.
(TIF)
Figure S3 Split channels of Figure 2 A and B.
(TIF)
Figure S4 Successful blocking of non-specific binding of
antibodies to the HSV1 Fc receptor, gE. (A) Cells
synchronously infected with VP26-GFP HSV1 (green) were fixed
and stained with rabbit antibody against histone H3, purified the
same way and diluted to the same concentration as the Sigma
rabbit anti-APP used in this paper. Cells were routinely stained in
parallel for all figures presented here for histone and for APP, with
identical blocking, incubations, washes, and secondary antibodies.
Images were captured with the same exposure settings. Note that
VP26-GFP viral particles in the cytoplasm are not stained with the
histone antibody while the nucleus is appropriately stained. Thus
the secondary antibody has no anti-viral activity, and the blocker
successfully eliminates Fc binding by the antibodies. (B) Histogram
showing a quantitative analysis of the immunostaining of anti-
histone antibodies (red). Most (86.967.2%) viral particles (green)
are not stained for histone (red). We counted 4791 viral particles in
19 cells from 3 independent experiments.
(TIF)
Figure S5 Co-localization of viral capsids (VP26-GFP,
green), viral envelope (gD, blue) and APP (red) after
synchronousinfectionwithVP26-GFPHSV1.Thisfigureisin
parallel to Figure 4, showing results for viral glycoprotein gD similar
tothose obtained for the other viral envelope glycoprotein, gE, at the
same time point. As for gE, the majority of the VP26-GFP particles
stainedforbothgDandAPP.(A)Anexampleofinfectedcellsstained
for gD (blue) and APP (red). (B) High magnification of the boxed
regions in (A). Arrows indicate those particles with all three labels.
Arrowheads indicate only gD (blue) or APP (pink). (C) Intensity
profile along a line (white) drawn across the merged image in (A).
Arrows indicate the superposition of peaks for each channel. (D)
Histograms showing the percentage of VP26-GFP particles in each
category. VP26-GFP alone (4.963.2%), with APP (4.062.4%), with
gD (22.265.9%), and with both APP and gD (69.367.6%).
Experiments were performed in triplicate, and 2228 particles in 10
cells were counted from each experiment were counted.
(TIF)
Figure S6 Gallery of viral configurations by thin section
immuno-gold electronmicroscopy showing abundant
gold particles decorating intracellular viral particles.
(A and C) Examples of APP-gold labeling of various types of viral
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also surrounded by an APP-gold labeled membrane. (B and D)
Non-relevant polyclonal rabbit antibodies did not label these
clusters or their surrounding membrane, nor other configurations
of virus and cellular membrane systems. (E) Gallery of examples of
APP-gold decorated viral particles. Scale bars=100 nm.
(TIF)
Figure S7 Cytoplasmic viral particles are associated with
microtubules. Cells mock-infected or infected with VP26-GFP
HSV1 (10 pfu/cell) at 7–9 hr p.i. were stained for b-tubulin (red) and
the nucleus with DAPI (blue). Images were captured with confocal
microscopy. (A) Normal microtubule distribution in mock-infected
cells. Microtubule organizing centers (MTOC) were clearly seen at
one side of the nucleus. (B) Abnormal microtubule distribution in
HSV1-PV26-GFP infected cells at 7–9 hr p.i. Note that all cells with
VP26-GFP display similar microtubule disarray. (C) A high
magnification zoom of a representative infected cell showing many
VP26-GFP particles in the cytoplasm apparently associated with
microtubules (arrowheads) (8760.1%, n=136 particles from 4 cells).
(TIF)
Figure S8 Out-going HSV1 particles display a wide
range of behavior. A) A gallery of movements of HSV1-APP
double-labeled particles (arrow) from another infected cell similar
to one the shown in Figure 8. Time-lapse sequences were captured
at 3-sec intervals. The last panel shows the trajectory of the HSV1-
APP vesicle. See Movie S5. (B) Another gallery of movements of
HSV1-APP tubules (arrow). Shown is a VP26-GFP particle (green)
moving within or upon a large APP-mRFP (red) tubule. The APP
tubule changes its shape during the sequence. This is a region of
interest taken from the infected cell shown in Figure 8a-b and
Movie S2.
(TIF)
Table S1 Comparison of movements of VP26-GFP and
APP-mRFP singly and together*.
(PDF)
Movie S1 APP stains gEnull viral particles. This sequence
shows the 3D rendering of a z-stack of the cell shown in Figure 3
that was infected with gE null virus (green) and stained for APP
(red) and DAPI (blue).
(MOV)
Movie S2 Transport of VP26-GFP particles with APP-
mRFP vesicles during viral egress. The cell expressing APP-
mRFP was infected with VP26-GFP HSV1 at 7 hr p.i.. The movie
is from a 300-frame sequence, taken at 3-sec intervals, and
displayed at 9 frames per second. A still frame and track tracing
from this video are shown in Figure 8a and b.
(MOV)
Movie S3 An example of VP26-GFP particles transport-
ing with APP-mRFP selected from Movie S1 showing the
movement of a single VP26-GFP-APP-mRFP (particle 1, as
indicated in Fig. 8b). The VP26-GFP/APPmRFP double-label
particle moves away from the nucleus towards the plasma
membrane at variable rates ranging from ,0.22–1.03 mm/sec
with no pauses. See Figure 9a for a gallery of these movements.
(MOV)
Movie S4 Another example of VP26-GFP particles
transporting with APP-mRFP selected from Movie S1. The
movement of a single VP26-GFP-APP-mRFP (particle number 2
as indicated in Figure 8b). The VP26-GFP/APPmRFP double-
label particle moves away from the nucleus towards the plasma
membrane at highly variable rates with many pauses, again
ranging from ,0.22–1.03 mm/sec. See Figure 9b for a gallery of
these movements.
(MOV)
Movie S5 Transport of VP26-GFP particles with APP-
mRFP captured from another experiment. Arrows show
the movements of VP26-APP double-label particles. Movie
sequences were captured at 7–9 hr p.i. with 3-sec time-lapse
intervals for 219 frames. See Figure S8A for a gallery of still
frames of these movements.
(MOV)
Movie S6 APP-mRFP associates with gEnull virus
labeled with VP26-GFP. Cells were first dually transfected
with pAPP-mRFP and pK26GFP, infected 48 hr later with gEnull
virus and then maged at 7–10 hr p.i.. Shown is a 51-frame time-
lapse sequence captured at 3-sec intervals of two adjacent cells
expressing both labels and infected with the gEnull virus.
(MOV)
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